TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05992376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
Study: NCT04966416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose in gelatine capsules.
Study: NCT05937321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share plus intervention
Description: Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Diabetes self-management education materials
Study: NCT05110105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive board game health education
Description: The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
Study: NCT05403736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Aggressive Risk MitigAtion Plan
Description: Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
Study: NCT06363786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test patches
Description: Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
Study: NCT06043141

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve ultrasound
Description: Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies
Description: Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
Study: NCT05110105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional health education
Description: The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
Study: NCT06127914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Early Infant Feeding Cues
Description: The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods.
Study: NCT06486181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombolysis/Thrombectomy
Description: Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT.
Study: NCT05625399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days
Study: NCT05692999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q6W
Description: Pembrolizumab 200mg Q6W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed 500 mg/m^2 Q3W
Description: Pemetrexed 500 mg/m\^2 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2 Q3W
Description: Pemetrexed 500 mg/m\^2 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Description: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Study: NCT06043141

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure pain threshold
Description: Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
Study: NCT05298020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 400mg,sc,d1,Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 210mg，CIV72h，d1-3，Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m2,iv,d1,d8,Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, iv,d1,d8，Q4W
Study: NCT06552429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Study: NCT05162586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran medium dose
Description: Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran medium dose
Description: Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to Enpatoran up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to Enpatoran up to 24 weeks.
Study: NCT05851677

Intervention type: DRUG
Intervention: Disitamab vedotin
Description: recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Study: NCT06557759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Calming Music
Description: Participants will listen to calming music, which may enhance health and wellness by reducing autonomic reactivity and improving bodily awareness, brain-body connection, and emotional wellbeing.
Study: NCT05988138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Promoting Positive Emotions
Description: An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
Study: NCT05489887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
Study: NCT06412445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation
Description: The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh
Description: The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
Study: NCT05451095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI 474121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06047899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin
Description: Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mannitol formulated for oral administration (capsules)
Study: NCT04732936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Peripheral Nerve Stimulator
Description: Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Peripheral Nerve Stimulator
Description: Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
Study: NCT04760392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-directed mobilization
Description: * A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists.
Study: NCT05339269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy
Description: The laparoscopic splenectomy is performed by the same surgical team.
Study: NCT05510115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
Study: NCT06274866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Individuals in the control group were followed up with an exercise training brochure.
Study: NCT05651555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution
Description: Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution
Description: Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
Study: NCT05451095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04190030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness training
Description: Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive reappraisal training
Description: Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
Study: NCT04583748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi Meditation
Description: Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
Study: NCT05684653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib Tablets
Description: 50 mg, single oral dose
Study: NCT04583748

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
Study: NCT04556370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Different infusion dose of norepinephrine simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Different infusion dose of norepinephrine simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Different infusion dose of norepinephrine simultaneous with subarachnoid block
Study: NCT05451095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: Ketamine hydrochloride
Study: NCT06011616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory training
Description: sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercises
Description: stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning